| EPA085 | Vitamin D supplementation enhances cytotoxic response in patients with severe COVID-19 | E-poster | Immune responses to SARS-Cov2 |
| EPA087 | Limited immunogenicity of SARS-CoV-2 vaccine in people living with HIV (PWH) and low nadir CD4 counts | E-poster | SARS-Cov2 vaccines |
| EPA088 | Adverse events following COVID-19 vaccination among people with HIV: review of available vaccine safety literature | E-poster | SARS-Cov2 vaccines |
| EPA089 | Potent cytotoxic activity against SARS-CoV-2 of CD8+ T cells from individuals with HIV who received complete schedule of COVID-19 vaccines | E-poster | SARS-Cov2 vaccines |
| EPA090 | Factors associated with SARS-CoV2 vaccination acceptance in people with HIV participating in the SCAPE-HIV study | E-poster | SARS-Cov2 vaccines |
| EPA091 | Immunogenicity of mRNA-1273 COVID-19 vaccination in PLWH after inadequate primary vaccination response | E-poster | SARS-Cov2 vaccines |
| EPA092 | SARS-CoV-2 Omicron Spike recognition by plasma fromindividuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses | E-poster | SARS-Cov2 vaccines |
| EPA093 | Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected Individuals not responding to the Ad26.COV2.S vaccine | E-poster | SARS-Cov2 vaccines |
| EPA094 | Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1 infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection | E-poster | SARS-Cov2 vaccines |
| EPB001 | Factors influencing immune restoration in people living with HIV/AIDS | E-poster | Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression |